BCR and acute lymphoblastic leukemia: To examine whether inhibition of BCR-ABL and TEL-ABL kinase activity suppresses PI3K signaling, ALL-LTCs were exposed to imatinib at 1μM for 20h and phosphorylation levels of AKT, S6 protein and 4E-BP1 were determined.